NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: A populationbased case-control study

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Masclee, Gwen M C ^a   Coloma, Preciosa M ^a   Spaander, Manon C W ^a   Kuipers, Ernst J ^a   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VERY ELDERLY; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; ODDS RATIO; REGISTER; RISK;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PROTON PUMP INHIBITORS; REGISTRIES; RISK; UNITED KINGDOM;

EID: 84922373073     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006640     Document Type: Article

References (53)

1. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med 2014;371: 836-45.
2. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103: 788-97.
3. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53: 1070-4.
4. de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: A Dutch nationwide cohort study. Gut 2010;59: 1030-6.
5. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-Analysis. Gut 2012;61: 970-6.
6. Globocan 2008 Worldwide Cancer Incidence M, Prevalence and Disability-Adjusted life years (DALYs) (accessed 11 Jul 2014).
7. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-Analysis. Am J Epidemiol 2008;168: 237-49.
8. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2010;8: 235-44; quiz e32.
9. Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: A meta-Analysis. Gastrointest Endosc 2008;67: 394-8.
10. Masclee GM, Coloma PM, de Wilde M, et al. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. Aliment Pharmacol Ther 2014;39: 1321-30.
11. WHO Global Health Observatory Data Repository. Cause-specific mortality, 2008: WHO region by country. http://apps.who.int/gho/data/node.main.887?lang=en (accessed 18 Oct 2013).
12. Cancer Research UK. Oesophageal cancer survival statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/survival/#Trends (accessed 18 Oct 2013).
13. Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012;24: 917-23.
14. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-Analysis. Gastroenterology 2003;124: 47-56.
15. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010;138: 2260-6.
16. Kantor ED, Onstad L, Blount PL, et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012;21: 456-61.
17. Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141: 2000-8; quiz e13-4.
18. Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a meta-Analysis. Br J Cancer 2009;100: 551-7.
19. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-Term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011;377: 31-41.
20. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: A systematic review and meta-Analysis. Gut 2014;63: 1229-37.
21. Sivarasan N, Smith G. Role of aspirin in chemoprevention of esophageal adenocarcinoma: A meta-Analysis. J Dig Dis 2013;14: 222-30.
22. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: A nested case control study in the UK. Gut 2006;55: 1538-44.
23. Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: A meta-Analysis. Br J Cancer 2014;110: 2378-88.
24. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012;142: 442-52.e5; quiz e22-3.
25. Nguyen T, Khalaf N, Ramsey D, et al. Statin use is associated with a decreased risk of Barrett's esophagus. Gastroenterology 2014;147: 314-23.
26. Singh S, Singh AG, Singh PP, et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: A systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2013;11: 620-9.
27. Rothman KJ, Greenland S, Lash TL. Causation and causal inference. Modern epidemiology. 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008.
28. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16: 393-401.
29. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: The IPCI project. Methods Inf Med 1999;38: 339-44.
30. Booth N. What are the read codes? Health Libr Rev 1994;11: 177-82.
31. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: The effect of fifteen years of evolution. Fam Pract 1992;9: 330-9.
32. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. http://www.whocc.no/atcddd/(accessed 4 Apr 2013).
33. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58: 2929-34.
34. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study. J Natl Cancer Inst 2002;94: 422-9.
35. Falk GW, Buttar NS, Foster NR, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012;143: 917-26.e1.
36. Lochhead P, Chan AT. Statins and colorectal cancer. Clin Gastroenterol Hepatol 2013;11: 109-18; quiz e13-4.
37. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103: 825-37.
38. Sadaria MR, Reppert AE, Yu JA, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011;142: 1152-60.
39. Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: Involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58(Suppl 3): 141-8.
40. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. Lancet Oncol 2005;6: 945-52.
41. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58: 635-41.
42. Suissa S, Dell'aniello S, Vahey S, et al. Time-window bias in case-control studies: Statins and lung cancer. Epidemiology 2011;22: 228-31.
43. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167: 492-9.
44. Azoulay L, Suissa S. Immortal person-Time bias in relation to the use of nonsteroidal anti-inflammatory drugs and statins in the prevention of esophageal cancer in patients with Barrett's esophagus. Gastroenterology 2012;142: E20-1; author reply e21.
45. Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013;11: 382-8.
46. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005;95(Suppl 1): S144-50.
47. Alexandre L, Clark AB, Bhutta HY, et al. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: A nested case-control analysis. Gastroenterology 2014;146: 661-8.
48. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27: 316-20.
49. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: Results from a large population-based study. J Natl Cancer Inst 2011;103: 1049-57.
50. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365: 1375-83.
51. Strom BL, Kimmel SE, eds. Textbook of pharmacoepidemiology. Chichester: John Wiley & Sons, 2006.
52. Hvid-Jensen F, Pedersen L, Funch-Jensen P, et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: A nationwide study of 9883 patients. Aliment Pharmacol Ther 2014;39: 984-91.
53. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014;147: 784-92.e9, quiz e13-4.